Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
932 4 |
Ultima descărcare din IBN: 2019-06-05 12:56 |
Căutarea după subiecte similare conform CZU |
616.12-08+615.22 (1) |
Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (975) |
Medicamentele potrivit acţiunii lor principale (390) |
SM ISO690:2012 GHICAVÂI, Victor, POVETKIN, Serghei, BACINSCHI, Nicolae, PODGURSCHI, Lilia, LEVAŞOVA, Oxana, ŢURCAN, Lucia, GUŞUILĂ, Gheorghe, NESTEROV, Maxim. Studiul farmacoepidemiologic al continuităţii tratamentului pacienţilor cu patologie cardiacă asociată în etapa de staţionar şi în cea ambulatorie. In: Sănătate Publică, Economie şi Management în Medicină , 2017, nr. 1(71), pp. 42-45. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | |||
Numărul 1(71) / 2017 / ISSN 1729-8687 /ISSNe 2587-3873 | |||
|
|||
CZU: 616.12-08+615.22 | |||
Pag. 42-45 | |||
Descarcă PDF | |||
Rezumat | |||
In the pharmacotherapy of patients with concomitant cardiovascular disease is important maintaining the continuity between the hospital and outpatient treatment. Pharmacoepidemiological study spent in hospitals in Kursk (Russia) and Chisinau (Moldova) has reported that during the pharmacotherapy of these patients were fulfilled the international and national recommendations for treatment of patients with coronary heart disease, arterial hypertension, chronic heart failure with the use of the modern drugs from groups of beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, nitrates, antiplatelets, statins, diuretics, myocardial cytoprotectors and there is adequate level of continuity between the hospital and outpatient stage of therapy in the both city: Kursk and Chisinau. |
|||
Cuvinte-cheie рharmacoepidemiological study, calcium channel blockers, angiotensin II receptor antagonists, beta-blockers, angiotensin converting enzyme inhibitors, diuretics |
|||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-55667</cfResPublId> <cfResPublDate>2017-02-28</cfResPublDate> <cfVol>71</cfVol> <cfIssue>1</cfIssue> <cfStartPage>42</cfStartPage> <cfISSN>1729-8687</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/55667</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Studiul farmacoepidemiologic al continuităţii tratamentului pacienţilor cu patologie cardiacă asociată în etapa de staţionar şi în cea ambulatorie</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>рharmacoepidemiological study; beta-blockers; calcium channel blockers; angiotensin converting enzyme inhibitors; angiotensin II receptor antagonists; diuretics</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'><p><em>In the pharmacotherapy of patients with concomitant cardiovascular disease is important maintaining the continuity between the hospital and outpatient treatment. Pharmacoepidemiological study spent in hospitals in Kursk (Russia) and Chisinau (Moldova) has reported that during the pharmacotherapy of these patients were fulfilled the international and national recommendations for treatment of patients with coronary heart disease, arterial hypertension, chronic heart failure with the use of the modern drugs from groups of beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, nitrates, antiplatelets, statins, diuretics, myocardial cytoprotectors and there is adequate level of continuity between the hospital and outpatient stage of therapy in the both city: Kursk and Chisinau.</em></p></cfAbstr> <cfAbstr cfLangCode='RU' cfTrans='o'><p><em>П р и п р о в е д е н и и ф а рм а ко т е р а п и и б о л ь н ы х с сочетанной сердечно-сосудистой патологией важным я в л я ет с я собл ю д е н и е п р е ем с т в е н н о с т и м еж ду стационарным и амбулаторным этапами лечения. Фармакоэпидемиологическое исследование, проведённое в лечебных учреждениях г. Курска (Россия) и г. Кишинэу (Республика Молдова), констатировало, что при проведении фармакотерапии этой категории больных соблюдаются международные и отечественные рекомендации по лечению больных ишемической болезнью сердца, артериальной гипертензией, хронической сердечной недостаточностью с применением современных препаратов из групп бетаадреноблокаторов, блокаторов каналов кальция, ингибиторов ангиотензин конвертирующего фермента, антагонистов рецепторов ангиотензина </em><em>II</em><em>, нитратов, антиагрегантов, статинов, диуретиков, миокардиальных цитопротекторов и существует достаточный уровень преемственности госпитального и поликлинического этапов терапии в лечебных учреждениях г. Курска и г. Кишинэу.</em></p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11721</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-52415</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10648</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-22820</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-52416</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-13831</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-39894</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-52417</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11721</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11721-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Ghicavîi</cfFamilyNames> <cfFirstNames>Victor</cfFirstNames> <cfFamilyNames>Гикавый</cfFamilyNames> <cfFirstNames>Виктор</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-52415</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-52415-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Поветкин</cfFamilyNames> <cfFirstNames>Сергей</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10648</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10648-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Bachinsky</cfFamilyNames> <cfFirstNames>N.G.</cfFirstNames> <cfFamilyNames>Бачинский</cfFamilyNames> <cfFirstNames>Николай</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-22820</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-22820-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Podgursky</cfFamilyNames> <cfFirstNames>L. A.</cfFirstNames> <cfFamilyNames>Подгурски</cfFamilyNames> <cfFirstNames>Лилия</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-52416</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-52416-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Levashova</cfFamilyNames> <cfFirstNames>Oxana</cfFirstNames> <cfFamilyNames>Левашова</cfFamilyNames> <cfFirstNames>Оксана</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-13831</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13831-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Цуркан</cfFamilyNames> <cfFirstNames>Лучия</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-39894</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-39894-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Guşuilă</cfFamilyNames> <cfFirstNames>Gheorghe</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-52417</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-52417-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2017-02-28T24:00:00</cfStartDate> <cfFamilyNames>Нестеров</cfFamilyNames> <cfFirstNames>Mаксим</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>